secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001558370-24-007051
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q1 revenue $11.3M (+32% YoY); updates 2024 SPL guidance to ~$5M
-----------------------------------------------------------------------

- Total revenue $11.3M, up 32% YoY; core revenue $8.2M, up 5%.
- SPL program-related revenue $3.2M, up 292% YoY; four new SPLs signed YTD including Be Biopharma.
- Net loss $9.5M vs $10.9M in Q1 2023; EBITDA loss $11.2M.
- 2024 guidance: core revenue flat to 5% growth; SPL revenue expected ~$5M (increase).
- Cash and investments $202.5M at March 31; expects year-end cash at least $175M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024007051/0001558370-24-007051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024007051/mxct-20240507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer